Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab as Neoadjuvant Therapy in Early Stage NSCLC
NCT02994576Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Dec 2016
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Gustave Roussy. Started Dec 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02994576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994576.